Isca Biochemicals

14/07/2026

RDP3 is a peptide derived from rice with tissue-penetrating capability, which can promote repair of oral ulcer mucosal in vivo and in vitro. Mechanistically, RDP3 functions as an antagonist of the interleukin-2 receptor β subunit (IL-2Rβ) with a binding affinity KD of 0.99 μM. This leads to suppression of IL-2Rβ/PI3K activity and blocks pathological PI3K signaling, inhibiting NLRP3/GSDMD-mediated pyroptosis, reducing inflammation, and promoting mucosal regeneration. RDP3 can not only accelerate wound healing but can also restore microbiome homeostasis.

15/06/2026

AurB is a novel cell-penetrating peptide, derived from the helical motif of of the bacterial cupredoxin auracyanin B (residues 61–88 ), AurB selectively enters human prostate cancer cells and localizes to mitochondria, where it blocks energy production by targeting ATP synthase, thereby significantly inhibiting tumour growth. In mice, combination treatment with aurB and radiation therapy significantly inhibits tumour growth in a tibial bone metastasis model, moreover the number of lung metastatic lesions is also significantly lower. Multiplex RNA expression profiling revealed that the inhibition of ATP production by aurB increases the efficacy of radiation therapy by modulating multiple pathways involving HIF-1α.

AurB is a novel cell-penetrating peptide, derived from the helical motif of of the bacterial cupredoxin auracyanin B (residues 61–88 ), AurB selectively enters human prostate cancer cells and localizes to mitochondria, where it blocks energy prod

30/03/2026

LA3IK is a novel Migration and Invasion Enhancer 1 (MIEN1) based hexapeptide, which is able to inhibit EGF mediated tumour progression in androgen independent, EGFR overexpressing PC3 prostate cancer cells. LA3IK selectively disrupts EGFR–ERBB2 heterodimerisation, reducing both phosphorylation of EGFR and downstream signaling through NF-κB, Src, and STAT3, leading to impaired EGF-driven migration and invasion while sparing proliferation. Transcriptomic analyses shows downregulation of the angiogenesis related genes ANGPTL4 and VEGFC. Crucially, LA3IK exhibits cancer selectivity, inhibiting EGF signaling in prostate tumours while preserving physiological EGFR function in healthy liver tissue.

LA3IK is a novel Migration and Invasion Enhancer 1 (MIEN1) based hexapeptide, which is able to inhibit EGF mediated tumour progression in androgen independent, EGFR overexpressing PC3 prostate cancer cells. LA3IK selectively disrupts EGFR–ERBB2 he

20/01/2026

WRPRFa is a peptide generated from a panel based on the ASIC3 modulating tetrapeptide RPRFa, by introducing changes at each each amino acid to understand their contribution to RPRFa activity. WRPRFa is the most potent ASIC3 activator to date, and has a specific intermolecular contact with the channel. WRPRFa stabilizes the activated state of ASIC3, increasing its sensitivity to protons and effectively removes acute desensitisation. ASIC3 can undergo tachyphylaxis at very acidic pH, which is accelerated by WRPRFa. WRPRFa is a selective and effective in vitro tool to study the interaction of RFamides and ASICs, and by extension gating mechanisms and the biophysics and biology of ASIC3.

WRPRFa is a peptide generated from a panel based on the ASIC3 modulating tetrapeptide RPRFa, by introducing changes at each each amino acid to understand their contribution to RPRFa activity. WRPRFa is the most potent ASIC3 activator to date, and has a s

02/12/2025

TAT (47-57) is a widely used and well characterised cell penetrating fragment of the HIV transactivator protein (TAT). TAT (47-57) is an arginine-rich TAT peptide which penetrates plasma membrane through passive diffusion to deliver a large variety of cargoes, from small particles to proteins, nucleic acids, and liposomes.

TAT (47-57) is a widely used and well characterised cell penetrating fragment of the HIV transactivator protein (TAT). TAT (47-57) is an arginine-rich TAT peptide which penetrates plasma membrane through passive diffusion to deliver a large variety of car

02/12/2025

Klotho-derived peptide 6 (KP6) binds to Wnt ligands and disrupts the engagement of Wnts with low density lipoprotein receptor-related protein 6 (LRD6), interrupting Wnt/β-catenin signaling. Klotho, an anti-aging protein, is kidney protective in Diabetic kidney disease (DKD). In vitro, KP6 prevents podocyte injury and inhibits β-catenin activation induced by high glucose without affecting Wnt expression. KP6 inhibits β-catenin activation in vivo and blocks the expression of its downstream target genes in glomerular podocytes and tubular epithelial cells. In DKD animal models, chronic infusion of KP6 reverses established proteinuria, attenuates glomerular hypertrophy, mitigates podocyte damage, and ameliorates glomerulosclerosis and interstitial fibrotic lesions.

Klotho-derived peptide 6 (KP6) binds to Wnt ligands and disrupts the engagement of Wnts with low density lipoprotein receptor-related protein 6 (LRD6), interrupting Wnt/β-catenin signaling. Klotho, an anti-aging protein, is kidney prote